iX Biopharma Ltd announced that on Apr, 8 2026 it allotted and issued 10.0 million new ordinary shares following the exercise of warrants at S$0.06 per share.

As a result, the company’s issued share capital has risen from 1,038,324,529 to 1,048,324,529 shares.

All 10.0 million shares were issued to Director and substantial shareholder Eddy Lee Yip Hang. The new shares rank pari passu with existing shares and are expected to begin trading on the Singapore Exchange on or around Apr, 10 2026.

To date, 17,565,084 warrants—representing 30.54% of all warrants originally issued—have been exercised. A total of 39,944,395 warrants remain outstanding, each exercisable at S$0.06 until Jul, 18 2026.